Imara wraps up a phase IIa in sickle cell with mixed results Jan. 6, 2021 By Lee Landenberger No Comments Imara Inc. reported a mixed bag of phase IIa study data for its lead candidate, IMR-687, for treating sickle cell disease in adults, bringing an end to a study that the company found cumbersome and that eventually stung its stock.Read More
Geron initiates phase III study of imetelstat in myelofibrosis refractory to JAK inhibitors Dec. 28, 2020 No Comments
DISC-0974 decreases hepcidin and increases transferrin saturation in inflammation models Dec. 28, 2020 No Comments
PKLR activator mitapivat shows promising preclinical data in murine hereditary spherocytosis Dec. 23, 2020 No Comments
RSS
